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1 
Introduction 
1.1 Of the 315 cases of AIDS reported in this country, (to 25 February, 1993), 144 
were drug use related; 1,381 persons had tested positive for the HIV antibody in the same 
period and almost 50% of these cases were drug use related. It is therefore apparent that 
injecting drug use is extremely high risk behaviour and an important source of 
transmission of the HIV virus in this country, Methadone therapy together with 
counselling and needle exchange are recognised strategies in preventing the spread of the 
HIV virus. 
However, the use of methadone presents problems for patients, pharmacists, doctors and 
health workers. This Group has addressed these difficulties in order to develop a practical 
protocol that will ensure maximum benefit for the patient while at the same time 
protecting the pharmacists, doctors and health workers involved in methadone therapy in 
the community. 
1.2 The National AIDS Strategy Committee has accepted the recommendations of the 
four sub-committees which it had previously established to examine various aspects of its 
brief. The Strategy Committee endorsed the recommendation that it would be necessary 
to allow methadone prescribing in the proposed satellite clinics in order to ensure that 
drug users availed of the full range of treatment services. It was also accepted that agreed 
protocols for the treatment of drug-using individuals needed to be established in order to 
avoid unnecessary pressure being placed on the general practitioner to prescribe opiates 
and other drugs. It was envisaged that this would also lead to the avoidance of double 
prescribing and inappropriate prescribing. The National AIDS Strategy Committee 
considered that the appropriate agencies to prepare such protocols were the Drug 
Treatment Centre, the Eastern Health Board, the Irish College of General Practitioners 
and voluntary drug agencies. 
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INTRODUCTION 
1.3 Accordingly, the Minister for Health established an Expert Group with the 
following membership to develop the protocol: 
Dr J. H. Walsh, Department of Health (Chairman) 
Dr. J. Barry, Drugs - HIV/AIDS Co-Ordinator, 
Eastern Health Board; 
Mr. T. Geoghegan. Project Leader, Merchant’s Quay Project; 
Dr. J. O’ Connor, Clinical Director, Drug Treatment Centre; 
Dr. F. O’ Kelly, Irish College of General Practitioners; 
Dr. B. Sweeney, Consultant Psychiatrist, 
Eastern Health Board, Psychiatric Services; 
Mr. D. Ryan, Department of Health, 
was appointed Secretary to the Group. 
1.4 The Group were asked to consider the following in particular: 
− methadone prescribing 
− registration of drugs users and 
− licensing of general practitioners to treat drug users, 
1.5 The Group gratefully acknowledges the submissions received from individuals and 
organisations which greatly assisted the Group in the preparation of this report. In 
particular the supportive and cooperative assistance offered by the Pharmaceutical 
Society of Ireland and the Irish Pharmaceutical Union was essential to the preparation of 
this report. The Group is also most appreciative of the work and support of the Irish 
College of General Practitioners in the areas of illicit drug use and drug addiction. 
1.6 The Group wishes to record its acknowledgement of the valuable contributions to 
the work of the Group made by Ms. S. Stafford Johnson, Senior Clinical Psychologist and 
Dr. E. Keenan, Senior Registrar, both of the Drug Treatment Centre. 
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2 
Community Based Treatment 
of Drug Users 
2.1 Methadone prescribing 
The National AIDS Strategy Committee accepted that the prescribing of methadone was 
necessary to ensure that drug users would be encouraged to avail of the full spectrum of 
preventative measures and treatment services. This is particularly significant in view of 
the preponderance of HIV/AIDS in the drug-using community resulting in the spread of 
the infection as a result of sharing of contaminated needles. The Group discussed its remit 
at some considerable length and finally agreed on the following basic tenets:- 
(i) That maintenance programmes represented, for many users, their most 
feasible option for stablising their addiction. These programmes had obvious 
attractions for service users. 
(ii) Methadone prescribing is important to ensure 
(a) that the maximum number of users avail of treatment services; 
(b) the prevention of transmission of the HIV virus through infected 
needles. 
(iii) That methadone is the most appropriate drug for use in a maintenance 
programme for addiction. The Group holds this view so strongly that it 
would specifically list the following drugs as being unsuitable for such 
programmes: 
Morphine (MST); Dihydrocodeine (DF118); 
Buphrenorphine (Temgesic); Dipipanone (Diconal); 
Dextromoramide (Palfium). 
The Group is aware that benzodiazepines have potential for abuse and some of them (e.g. 
Flunitrazepam (Rohypnol) and Temazepam (Normison)) are being injected thus perhaps 
contributing to the transmission of HIV. The Group recognises that benzodiazepines are 
useful in the short term treatment of anxiety and insomnia but stress that prescribing 
doctors should be aware of the abuse associated with them. 
 
 
4 
2.2 Methadone, like any other addictive drug, is liable to abuse from a number of 
sources. Therefore, a number of safeguards must be introduced to avoid problems caused 
by double prescribing and its subsequent availability on the black market. Consequently 
it was agreed that control of methadone prescribing was essential. This allows the 
following advantages: 
(a) the protection of the service and its users 
(b) the protection of the service providers 
(c) an aid to appropriate and responsible prescribing 
2.3 The Group recognised the validity of Dr. John O’ Connor’s guidelines entitled: 
Good Clinical Practice in Relation to Methadone Prescribing as a basis for clinical 
practice. Dr. O’ Connor’s paper is reproduced at Appendix A. 
2.4 In recognition of the complexities of the medical and psycho-social issues involved 
in the treatment of drug use the Group considered that the importance of a 
multidisciplinary approach should be emphasised. The Group considered that a “team 
approach” to the admission of a patient to a methadone prescribing regime was most 
important. This issue is expanded upon later in this report. 
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3 
The Role of the General Practitioner in Community 
Methadone Maintenance Programmes 
3.1 The Irish College of General Practitioners has stated in its Policy Statement on 
illicit Drug Use and Problems of Drug Addiction that the College supports the provision 
of community drug teams and that these teams should work closely with local general 
practitioners. Doctors who wish to prescribe for patients with addiction problems should 
do so only when satisfied about the adequacy of support from the statutory and voluntary 
services and the availability of proper resources. The Group endorses this view and 
would stress that such prescribing should be within the guidelines issued by the Medical 
Council for the prescribing of controlled drugs. (The Medical Council Guidelines are at 
Appendix B). 
3.2 In practice it is recommended that a person in difficulty with his/her drug use 
should be referred either to the Drug Treatment Centre or to the local health board 
addiction services or to the local community drug team for a full assessment, including a 
psychiatric evaluation. The initial referral could be from the individual’s own doctor, 
public health nurse, drugs out-reach worker, voluntary agency or by self-referral. 
Following assessment it is recommended that the individual should be offered a range of 
options including detoxification, support for a drug-free life, referral to a programme of 
rehabilitation, or a methadone maintenance programme. A key drug worker would be 
identified to work with this person on an on-going basis. After stabilisation as drug-free 
or on a maintenance programme the individual would be introduced to a local doctor who 
had agreed to continue medical care and/or methadone maintenance at a level agreed 
between the doctor, the patient and the addiction services. The Group endorses the role of 
the community drug team and recommends the urgent establishment of other community 
drug teams in areas of greatest need. 
3.3 There should be regular communication between the doctor and the addiction 
services through the patient’s key drug worker. This should ensure that any problems 
which arise concerning the 
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treatment are quickly identified and dealt with at the most appropriate level. This would 
give support and protection to the patient, the doctor and the addiction services. The 
Group therefore recommends that close co-operation should exist between general 
practitioners and the community drug team/addiction services for their area. 
This would also have the effect of establishing the practice of “good care” in the 
prescribing of methadone to opiate-addicted individuals. All doctors would be 
encouraged to accept that this was the preferred treatment option for these problems. 
General practitioners using such a system of care would work in cooperation with their 
local pharmacy colleagues, A nominated pharmacist would dispense for each individual 
drug user on a treatment or maintenance programme and therefore the role of the 
pharmacist will be essential in the on-going development of community drug teams. 
3.4 It is considered that general practitioner sessions would initially take place in the 
community based (satellite) clinics but ultimately it is envisaged that the scheme would 
develop to the point where participating general practitioners would see patients in their 
own surgeries. 
3.5 In providing this service the general practitioner would be strongly supported by 
the appropriate addiction service and by the community care services of the health 
boards. Liaison with acute and chronic hospital services dealing with HIV/AIDS cases 
will need to be fully developed to ensure that the service is as integrated and efficient as 
possible. 
3.6 The Group recognises that there are general practitioners who are already 
prescribing methadone for patients in the community. As previously stated there are 
considerable difficulties for all concerned if doctors treat patients in isolation. 
Accordingly it is recommended that such doctors should contact the Drug Treatment 
Centre or the health board addiction services in order that their patients can avail of the 
full range of services available and to ensure 
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patients can avail of the full range of services available and to ensure that their own 
service is supported and protected (i.e. against the possibility of double-prescribing etc.). 
3.7 The Group regards the support of the Drug Treatment Centre and of the health 
board addiction services as being vital to any methadone maintenance programme and 
would therefore recommend in the strongest possible terms that general practitioners 
should not become involved in the provision of such services unless they are provided in 
co-operation with the Centre and /or the addiction services. 
3.8 It is important that all statutory and voluntary bodies working in the area of drug 
use and HIV/AIDS have good communications and work closely together to ensure 
maximum cooperation in order that an optimal level of services are provided to drug 
users and their families. This would serve to help them as individuals and also to prevent 
the spread of HIV infection which is associated with the identified drug use problem 
concentrated in certain areas of Dublin City. 
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4 
Registration of Drug Users 
4.1 Registration of drug users 
The Group regarded the issue of the registration of drug users as crucial and were 
cognisant of the need to reach agreement on a formula which would be generally 
acceptable to all the relevant parties. It was agreed that there was widespread resistance 
to the term ‘register’ and accordingly it was decided that the use of the term ‘register’ was 
unnecessary and unwelcome. 
However, it was agreed that a basic level of control had to be introduced in order: 
(a) to protect the service 
(b) to protect service users; 
(c) to protect the service providers 
(d) to avoid double prescribing 
4.2 Treatment Card 
Having regard to the fact that the Group was established to give effect to proposals that 
services should, as far as possible, be decentralised or community-based it was agreed 
that if a common method of entry to the community-based treatment/addiction services 
could be agreed then the above-mentioned objectives could be achieved. In recognition of 
the fact that there might be a certain hesitancy and anxiety concerning the provision of 
services to drug users at local community level, it was agreed that a treatment card should 
be introduced to help allay some of these fears. It was decided that a treatment card 
should be provided for each patient who is admitted to the detoxification/maintenance 
programmes in the community. Following the initial assessment and period of 
stabilisation a patient may be issued with a treatment card and referred to an agreed local 
general practitioner and pharmacist. 
The card would remain the property of the patient at all times. The creation of a treatment 
card for a particular individual would be the outcome of a consultative process 
emphasising the benefits accruing 
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to both the service user and to the service provider. One of the obvious benefits would be 
that it would facilitate integration into the community and therefore the provision of such 
a card for each treatment user would be desirable and welcomed by both service users 
and providers. 
It is recommended that the following should be included on the treatment card: 
the name of the patient 
the date of birth of the patient 
a photograph of the patient 
the name of the prescribing doctor 
It is also recommended that the card should be deposited with the pharmacist or 
appropriate dispensing service by the patient for the duration of his/her treatment 
programme, 
Acceptance of the card by the pharmacist would not of itself permanently bind him/her to 
provide services for a particular patient. Likewise the patient could withdraw the card, for 
example on termination of his/her treatment programme. In order to avoid as far as 
possible future problems of stolen or mislaid cards and to allay any unwarranted concerns 
regarding confidentiality, it is recommended that each card should be valid for a specific 
period and should carry an expiry date after which a new card would be required for 
continuation of treatment. It is recommended that the cards should issue from two sources 
only; the Drug Treatment Centre, and the health board addiction services. 
4.3 Treatment list of service users 
In tandem with the proposed treatment card the Group agreed that there was a clear need 
for a list of patients to be maintained centrally not least for purposes of assessing both 
current levels of service provision, and of future trends. Having regard to all the 
circumstances it was agreed that the Drug Treatment Centre (Trinity Court), would be the 
preferred centre where such a list should be maintained. This would have a number of 
advantages including the most obvious that there would be a central resource which 
would have basic identifying details of all patients seeking treatment throughout the 
country. The proposed list would include details such as the patient’s name and date of 
birth. A patient’s name will be deleted from the list after an appropriate period out of 
treatment, 
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usually one year. 
It is recommended that for the purposes of co-ordination, each health board providing a 
service such as has been described, should designate a doctor to form a Liaison Group 
with the Clinical Director (or his deputy) of the Drug Treatment Centre for the purposes 
of ensuring the protection of users/providers, the services and the avoidance of double 
prescribing. 
The Group wishes to place particular emphasis on two issues in this general area: 
(a) Confidentiality: in this regard it is recommended that because of the nature of the 
information, access to the list should be restricted to doctors providing treatment. The 
maintenance of the list will, of course, comply with the provisions of the Data Protection 
Act, 1988. In accordance with the provisions of the Act, individuals who believe that 
information is being maintained on computer will be able to apply for disclosure of such 
information in accordance with the usual procedures. 
(b) Liaison and Co-operation: the Group wish to stress the need for a high level of 
liaison and co-ordination between the designated doctors who will have responsibility for 
the maintenance/operation of the list. 
Unlinked statistics will, of course, be available to the Department of Health, and other 
interested agencies. 
In order to avoid any undue pressure being put on the designated doctors to release 
information, the Group wish to stress that the list is a treatment list, and is not to be 
anything other than such a list. The Group would also wish to emphasise that where 
information is sought regarding a particular individual it should be sought from the initial 
referring doctor. 
4.4 Dispensing of Methadone 
The Group met with the Irish Pharmaceutical Union (ECU) and the Pharmaceutical 
Society of Ireland (PSI). The Group was most encouraged by the positive response of 
both organisations and their willingness to encourage their members to support the 
proposed initiatives. In practice it was agreed that the community-based 
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pharmacist would only dispense methadone to an individual for whom he/she held a 
treatment card. The prescription issued by the doctor would be marked “To be dispensed 
in --------------- pharmacy only” which would be an additional safeguard against double 
prescribing. It was agreed that the particular time of delivery and collection of 
prescriptions by users should be agreed locally in order to minimise disruptions to the 
other activities of the pharmacy and to enable the pharmacist to order methadone as it 
was required rather than to force the retention of excessive quantities in stock. The Group 
were strongly of the view that methadone should be dispensed in the same manner as any 
other similar medication. Individuals should not be forced to consume the methadone on 
the premises. 
4.5 The Group were aware that some drug users may not have access to dispensing 
community pharmacies. In such cases the Group recognises the validity of centralised 
arrangements for the dispensing of methadone. 
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5 
Licensing of General Practitioners 
to treat Drug Users 
5.1 The Group recognised that this was a very contentious area not least because of the 
difficulty of involving general practitioners in the treatment of drug users. The National 
AIDS Strategy Committee had envisaged that with the provision of adequate facilities 
and safeguards general practitioners would be prepared to take on a comprehensive role 
in the care and treatment of drug users. The Group, however, was of the view that 
licensing would be perceived as very much a negative step and would be opposed by the 
doctors and their representative organisations. It might, therefore, discourage general 
practitioners from becoming involved in the provision of services. 
5.2 The Group considered that the need for such a form of control would be partially 
obviated by the introduction of the treatment card, as recommended earlier in this Report. 
The introduction of guidelines for good practice will also assist in clearly defining the 
role of the general practitioner in the treatment of drug users. As previously stated in 
Paragraph 3.3 the Group strongly recommend that the prescribing of methadone should 
only take place within the context of a recognised treatment programme with active 
support from the various addiction services, statutory or voluntary, and following the 
guidelines recommended by this Group. 
5.3 The Group did recognise the value of registration of general practitioners as a 
positive measure rather than as a means of imposing restrictions or control. A scheme, 
similar to the combined ante-natal care scheme was suggested, whereby doctors would 
contract to provide care under agreed conditions and for agreed remuneration. Any doctor 
would be eligible to apply to participate in the scheme to the appropriate health board. 
The doctor would keep a list of consultations which would be forwarded for review by 
the appropriate medical officer and passed for payment in due course. 
 
 
 
 
13 
6 
General Issues 
6.1 Co-ordination and co-operation 
The Group are very aware that the recommendations which are contained in this report 
have wide-ranging implications for the delivery of services to drug users. The measures 
which are recommended will change existing services and offer clear guidelines for the 
delivery of new evolving services. The Group fully appreciates the difficulties that could 
arise in the implementation of the recommendations it has made and reiterates the need 
for the closest possible co-operation and liaison in the delivery of the services. 
This Group is confident that the support and co-operation which has been promised by all 
concerned will help to avoid many difficulties which might otherwise occur. However, in 
order to ensure that any difficulties which do arise are dealt with as expeditiously as 
possible, in the operation of the protocol and in the implementation of the other 
recommendations contained in this Report, the Group recommends that it should continue 
in existence for an initial phase-in period of twelve months in order to monitor and 
evaluate the proposed arrangements. At the end of this period the situation and necessity 
for such a Group should be reviewed. 
6.2 The following are areas of concern which the Group believe should be monitored 
for an initial period: 
(i) co-operation and liaison between the various addiction services both 
statutory and voluntary; 
(ii) co-operation and liaison between the doctors designated by the Drug 
Treatment Centre and the health board addiction services in the operation of 
the treatment list. 
(iii) the avoidance of double prescribing and inappropriate prescribing by the 
implementation of the Group’s recommendations and, in particular, the 
operation of the proposed treatment card. 
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7 
Summary of Recommendations 
(i) It is recommended that methadone is the most appropriate drug for use in a 
maintenance programme 
(ii) It is recommended that doctors who wish to prescribe for patients with addiction 
problems should do so only when satisfied that they are complying with the 
Medical Council guidelines on the prescribing of controlled drugs and where there 
is satisfactory support from the statutory and voluntary 
(iii) It is recommended that before a person is admitted to a maintenance programme 
he/she should be referred either to the Drug Treatment Centre or to the local health 
board addiction services or to the local community drug team for a full assessment 
including psychiatric evaluation. 
(iv) It is recommended that, following assessment, the individual should be offered a 
range of options including detoxification, support for a drug-free life, referral to a 
programme of rehabilitation, or a methadone maintenance programme. 
(v) The group recommends the urgent establishment of other community drug teams 
in areas of greatest need. 
(vi) The Group recommends that close co-operation should exist between general 
practitioners and the community drug team for their area. 
(vii) It is recommended that doctors who are currently treating patients with methadone 
should contact the Drug Treatment Centre or the health board addiction services in 
order that their patients can avail of the full range of available services and to 
ensure that their own service is supported and protected. 
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(viii) It is recommended that a treatment card should be provided for each patient who 
is admitted to detoxification/maintenance programmes in the community and that 
each card should be valid for a specific period. 
(ix) It is recommended that the card should issue from two sources only; the Drug 
Treatment Centre and the health .........................board addiction services. 
(x) It is recommended that a list of all patients on methadone therapy should be 
maintained and operated by a liaison group consisting of a designated doctor from 
each health board addiction service and the Clinical Director (or his deputy) of the 
Drug Treatment Centre. 
(xi) It is recommended that because of the confidential nature of the information, 
access to the list should be restricted to doctors providing treatment and comply 
with the guidelines set out by the Medical Council and the Data Protection Act. 
(xii) It is recommended that community-based pharmacists should only dispense 
methadone for individuals for whom they hold a treatment card and that 
methadone should be dispensed in the same manner as any other similar 
medication. 
(xiii) It is strongly recommended that the prescribing of methadone should only take 
place within the context of a recognised treatment/maintenance programme 
encompassing support from the various addiction services, statutory or voluntary, 
and following the guidelines recommended by this Group. 
(xiv) It is recommended that the Group should continue to monitor and evaluate the 
proposed arrangements and their operation for an initial phase-in period until the 
measures recommended in this report are operating satisfactorily. 
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APPENDIX A 
Good Clinical Practice in Relation 
to Methadone Prescribing 
____________ 
Dr. John J. O’ Connor 
Consultant Psychiatrist/Clinical Director 
January 1993 
THE DRUG TREATMENT CENTRE BOARD 
Trinity Court 
30/31 Pearse Street Dublin 2 
Telephone 677 1122 
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Methadone has a similar pharmacological spectrum to heroin. It is usually taken orally 
and in view of its longer half-life can be given on a once daily dosage thus ruling out the 
need to inject drugs and the drug-seeking behaviour, that ensues. 
MEDICAL: Medical examination should include assessment of respiratory, 
cardiac, G.I.T. and C.N.S. systems. The medical evaluation should also include 
examination of a patient’s upper and lower limbs and groin i.e. injection sites. 
PSYCHIATRIC: Psychiatric evaluation includes examination for any co-existing 
personality disorder, mild mental handicap, psychotic or depressive illness, 
SOCIAL: Social history should be obtained at this stage and where possible a 
collateral history from a relative or concerned person. 
URINALYSIS: Obtaining urine should be supervised and analysis carried out for the 
following reasons: 
(a) urine checked for particular drugs of abuse, and that the results are 
consistent with the patient’s history; 
(b) to ensure that the patient is not already receiving methadone elsewhere. 
TREATMENT PLAN: Methadone Detoxification/Maintenance 
The decision as to whether a patient should be given a detoxification or maintenance is 
based on a number of factors. It is good clinical practice to encourage a patient on first 
presentation to become drug free and avail of the opportunity for an independent lifestyle. 
Maintenance is usually decided as the best option if: 
(a) previous failed detoxifications 
(b) inability to remain drug free 
(c) length of time abusing drugs 
(d) physical ill health: medical problems including HIV 
(e) in the case of women - pregnancy 
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For a withdrawal regime a starting dose on 30-40 mgs ought to be sufficient, and 
thereafter reducing by 5 mgs every three days. It should be remembered that 
psychological factors play a large part in the manifestations of the withdrawal syndrome 
and a supportive reassuring approach can often greatly reduce the severity of the 
symptoms experienced. 
Many patients are not as physically dependent on opiates as they assume, particularly if 
they have been using heroin which can be very impure. Dublin street heroin is on average 
only 10 - 15 % pure. It is better to prescribe a lower dose and then increase it if the 
person is experiencing withdrawal symptoms than to prescribe a level that will induce 
intoxication and increase physical tolerance. Methadone should initially be administered 
on a daily basis and evidence of improvement in drug taking behaviour should include 
reference to regular supervised urinalysis. A few days supply of methadone should only 
be given to those who cope well with daily administration. 
A patient presenting in obvious withdrawals can either be given symptomatic relief with 
melleril, ponstan and lomotil or a low dose of methadone followed by referral the next 
day to a treatment centre. 
ABUSE POTENTIAL: The potential for abuse of methadone should not be forgotten. 
Already there is a thriving black market for methadone on the street. To combat this and 
the problem of double scripting it is essential, that a central register for methadone 
prescribing be instituted immediately. 
Finally, methadone should not be seen as an easy solution to a complex problem. 
Methadone should always be regarded only as an adjunct to treatment and not treatment 
per se. 
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APPENDIX B 
RECOMMENDATIONS 
OF THE MEDICALCOUNCIL 
FOR THE PRESCRIBING OF CONTROLLED DRUGS UNDER 
THE MISUSE OF DRUGS ACT, 1977 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Issued on behalf of the Medical Council and the Pharmaceutical Society of Ireland. Japan 1987 
1 Practitioners must ensure that all prescriptions for controlled 
drugs are written in the format specified in the Misuse of Drugs 
Regulations. Incorrectly written prescriptions cannot lawfully 
be dispensed by pharmacists. 
2 Practitioners and pharmacists in each area should reach an 
understanding about prescribing and dispensing controlled 
drugs. On the basis of such understanding pharmacists should 
be in a position to meet the legitimate needs of patients 
promptly. 
3 Practitioners should not treat patients from outside their 
practice areas for addiction problems by prescribing controlled 
drugs. Practitioners are advised to refer such patients to 
recognised drug treatment centres. 
4 Patients should be discouraged from moving from pharmacy to 
pharmacy with prescriptions for controlled drugs. 
5 A practitioner who has patients referred from a drug treatment 
centre for continuation of treatment, with the patient’s consent, 
should discuss the likely treatment regimen with the patient’s 
pharmacist. 
6 Doctors should report problems in the prescribing of controlled 
drugs to the Medical Council. 
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